Clinical studies with patients with early hematological malignancies (ie, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or stage 0/1 chronic lymphocytic leukemia) suggest that early intervention with curcumin, derived from the spice turmeric, may lead to prolonged survival and delay in progressive disease in some of these patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759937 | PMC |
| http://dx.doi.org/10.1177/1534735415622013 | DOI Listing |
Publication Analysis
Top Keywords
b-cell disorders
4
disorders curcumin
4
curcumin clinical
4
clinical studies
4
studies patients
4
patients early
4
early hematological
4
hematological malignancies
4
malignancies monoclonal
4
monoclonal gammopathy
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!